NCT01797094

BOTOX® in the Treatment of Upper Facial Lines in Japan

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 101 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 20 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) for the treatment of upper facial lines (Crow's Feet Lines and Frown Lines).

Conditions

• Upper Facial Rhytides
• Crow's Feet Lines
• Glabellar Lines
• Frown Lines

Interventions

Type	Name	Description
BIOLOGICAL	botulinum toxin Type A (44U)	44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
BIOLOGICAL	botulinum toxin Type A (32U)	32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.

Timeline

• Start date: 2013-02-01
• Primary completion: 2013-07-01
• Completion: 2014-07-01
• First posted: 2013-02-22
• Last updated: 2015-02-10
• Results posted: 2015-02-10

Locations

1 site across 1 country: Japan